沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤的疗效及对患者血清VEGF水平的影响

Therapeutic Effect of Thalidomide Combined with CHOP Regimen on Diffuse Large B-cell Lymphoma and the Effect of Serum Vascular Endothelial Growth Factor Level

目的探讨沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤的疗效及对患者血清VEGF水平的影响。方法选取74例弥漫大B细胞淋巴瘤患者,随机将其分为试验组(n=37)和对照组(n=37)。对照组采用CHOP方案治疗,试验组采用沙利度胺联合CHOP方案治疗。对比2组不同的治疗方案的应用效果,并分析其对血清VEGF水平的影响。结果试验组的临床治疗总有效率、完全缓解率明显高于对照组(P<0.05)。试验组的3年生存率明显高于对照组(P<0.05),试验组的死亡率和复发率明显低于对照组(P<0.05)。试验组和对照组的不良反应发生率差异不显著(P>0.05)。治疗前2组患者的血清VEGF水平差异无统计学意义(P>0.05),治疗后试验组的血清VEGF水平明显低于对照组(P<0.05)。结论沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤的疗效确切,安全性高,远期疗效显著,并可以有效降低患者的血清VEGF水平,值得在临床中应用推广。

Objective To investigate the efficacy of thalidomide combined with CHOP regimen in the treatment of diffuse large B-cell lymphoma and the effect of serum vascular endothelial growth factor level.Methods 74 patients with diffuse large B-cell lymphoma were randomly divided into the experimental group(n=37)and the control group(n=37).The control group was treated with CHOP regimen,and the experimental group was treated with thalidomide combined with CHOP regimen.The effects of different treatment schemes were compared between the 2 groups,and their effects on serum levels of vascular endothelial growth factor were analyzed.Results The total effective rate and complete remission rate of the experimental group were significantly higher than those of the control group(P<0.05);the 3-year survival rate of the experimental group was significantly higher than that of the control group(P<0.05);the mortality and recurrence rate of the experimental group was significantly lower than that of the control group(P<0.05);the incidence of adverse reactions between the experimental group and the control group was not significantly different(P>0.05);There was no significant difference(P>0.05).The serum VEGF level in the experimental group was significantly lower than that in the control group(P<0.05).Conclusion Thalidomide combined with CHOP regimen is effective,safe and effective in the treatment of diffuse large B-cell lymphoma.It can effectively reduce the serum level of vascular endothelial growth factor in patients with diffuse large B-cell lymphoma.It is worthy of clinical application and promotion.